2025年6月10日，北京普惠健康保官方发布的年度特药清单引起了人们的极大关注。在这份清单中，药 品从106种扩容至121种。其中，北京天竺综合保税区的5款海外特药被纳入报销范围，成为本次调整的 一大亮点。这也就意味着，参保人无需辗转海南，在市内定点医疗机构即可享受北京普惠健康保的一站 式特药报销服务。 这一政策的推出和实施，与人大代表几年来持续的呼吁与推动密不可分。过去一年，市人大代表提出的 每一份建议，背后都承载着沉甸甸的民意。这些建议不仅得到了承办单位的高度重视和高效办理，更在 跟踪问效中持续深化，推动"解决一件事"不断向"解决一类事"迈进。 2025年5月20日，市人大代表工委、市委社会工作部组织市公安局、市司法局、市高法等有关单位同人 大代表，围绕"关于基层减负的意见建议"进行调研座谈。 成绩单 2025年以来，市人大代表围绕首都所需，紧盯民之所盼，依法履职尽责，对全市各方面工作提出建议 973件，包括大会期间建议946件、闭会期间建议27件，已全部办复。市人大常委会代表工委主任李文总 结，代表建议呈现出紧扣全市中心工作、聚焦群众急难愁盼、适应新时代新要求、广泛吸纳民意4方面 特点。 持续发力 让罕 ...

Core Insights - The introduction of the Johnson & Johnson Impella heart pump marks a significant advancement in the treatment of critical heart diseases in China, being the first clinically urgent medical device approved for importation [1][3] - The successful signing at the China International Import Expo highlights the collaboration between various governmental and healthcare entities to facilitate the import of this life-saving technology [1][3] Group 1: Product and Market Impact - The Impella heart pump is the only FDA-approved device of its kind globally, designed for patients undergoing high-risk PCI procedures or experiencing cardiogenic shock, providing effective circulatory support and improving survival rates [3] - The import of the Impella pump is seen as a model for accelerating the introduction of more innovative overseas medical devices and drugs into the Chinese market, ultimately benefiting domestic patients [3] Group 2: Policy and Future Developments - The Tianzhu Comprehensive Bonded Zone is rapidly advancing its Rare Disease Drug Guarantee Pilot Zone, aiming to facilitate the import of more urgently needed medical products [4] - The initiative is part of a broader strategy to enhance the pharmaceutical industry in Beijing, ensuring that critical medical supplies can be imported efficiently to meet public health needs [4]

Core Insights - The Ruijin Hainan Hospital has successfully implemented 186 licensed medical device projects, 2 special medical foods, and 5 biomedical new technologies by the end of September this year, benefiting over 26,800 patients [1] - The unique drug Vusonatide, which treats achondroplasia, completed its first treatment in China at this hospital less than a year after its launch in the EU [1] - The hospital aims to leverage its public hospital platform to enhance the regional medical ecosystem and promote high-quality development of the healthcare industry in Hainan Free Trade Port, with a goal to serve nationwide and radiate to Southeast Asia [1] Group 1 - The hospital's achievements in licensed medical projects demonstrate its capability in addressing the availability of innovative medical solutions [1] - The real-world research conducted by the hospital accelerates the process of effective and widespread use of international innovative drugs and devices in China [1] - The establishment of the national regional medical center aims to enhance healthcare services and innovation in the region [1]

Core Viewpoint - Ruijin Hainan Hospital is leveraging institutional innovation to establish itself as a new highland for international medical services in the Hainan Free Trade Port, aiming to connect global medical resources with local patients [3][4][5]. Group 1: Institutional Innovation and Medical Services - Ruijin Hainan Hospital is a key project approved by the Hainan provincial government, officially starting operations in December 2021 and achieving full medical process integration by March 2022 [3][4]. - The hospital has successfully implemented 186 special drug and medical device projects, benefiting over 26,800 patients, significantly reducing the economic burden on patients by negotiating lower prices for these products [5][6]. Group 2: Real-World Research and Clinical Advancements - The hospital is conducting high-quality real-world data research to accelerate the registration and market entry of international innovative drugs and devices in China, exemplified by the rapid approval of Isatuximab injection for multiple myeloma patients [6][7]. - Innovative mechanisms have been established, including a dedicated technical expansion department and a patient management platform, to enhance the accessibility of quality medical resources [6][9]. Group 3: Talent Development and Cultural Integration - The hospital is focusing on a "transfer and cultivate" approach to talent development, aiming to instill the spirit of Ruijin Hospital in Hainan while building a sustainable local talent pool [7][8]. - Collaborative initiatives with Shanghai Jiao Tong University and other institutions are being pursued to provide local talents with international learning and research opportunities [8]. Group 4: Regional Medical Ecosystem and Internationalization - Ruijin Hainan Hospital is enhancing the regional medical ecosystem through platform sharing and resource integration, collaborating with local hospitals to provide high-quality medical services [9]. - The hospital is actively pursuing international cooperation, including partnerships with Southeast Asian medical institutions and exploring international insurance models to improve service standards [9].

Core Insights - The construction of Beijing's "Two Zones" (National Service Industry Expansion Pilot Zone and Free Trade Pilot Zone) has shown significant progress over the past five years, enhancing the city's capacity to attract foreign investment and support enterprises going global [1] Legal Environment Optimization - Beijing has approved the establishment of the Beijing International Law and Business Integration Demonstration Zone, covering 7.04 square kilometers in the CBD, focusing on international business cooperation and overseas service environments [2] - The region hosts over 30% of the city's legal service institutions and has established an international commercial arbitration center, enhancing legal support for businesses [2] - The initiative aims to attract global high-end resources and provide high-quality, international legal and business services to foster economic development in the capital [2] Data Facilitation - The Beijing CBD Service Station has launched a "online + offline" dual service model to assist companies with data compliance and cross-border data flow [3] - Since its operation began in 2024, the service station has supported over 50 companies across various sectors, including pharmaceuticals and banking, in meeting their cross-border data service needs [3] - Future plans include hosting specialized sessions on data security and compliance to further enhance companies' capabilities in data export [3] Rare Disease Medication Accessibility - Beijing has initiated the country's first pilot zone for rare disease medication assurance, exploring clinical application models for imported drugs not registered in China [4] - From April 2024 to July 2025, the Beijing Children's Hospital has successfully applied for temporary imports of a rare disease medication, with a total of 4,460 units approved within an average of 40 days [4] - This efficient approval process has transformed the previous situation of patients waiting for medication, ensuring continuous access to necessary drugs for rare disease patients [4] Global Innovation Drug Market - The pilot zone model in Beijing has demonstrated the convenience of the entire process from diagnosis to medication for rare disease patients, attracting attention from foreign enterprises [5] - The model has highlighted the potential of the Chinese market for global innovative drugs, providing a replicable experience for the registration and use of these drugs in China [5] - The successful promotion of this model is expected to accelerate the entry of global innovative drugs into the Chinese market [5]